{"id":"pegylated-interferon-alfa","safety":{"commonSideEffects":[{"rate":"50-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"30-60","effect":"Headache"},{"rate":"25-50","effect":"Myalgia"},{"rate":"20-40","effect":"Depression and mood changes"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-25","effect":"Neutropenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"5-15","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon-alfa is a cytokine that activates natural killer cells, macrophages, and T cells to mount antiviral and anti-proliferative responses. Pegylation (attachment of polyethylene glycol) extends the drug's half-life and reduces immunogenicity, allowing for less frequent dosing while maintaining therapeutic efficacy. This formulation is used primarily in chronic viral infections and certain malignancies.","oneSentence":"Pegylated interferon-alfa is a modified form of interferon-alfa that binds to interferon-alfa receptors on immune cells to enhance antiviral and anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:10.451Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"},{"name":"Certain hematologic malignancies (e.g., chronic myeloid leukemia, melanoma)"}]},"trialDetails":[{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":"Adult T-cell Leukemia-Lymphoma, ATLL","enrollment":15},{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":"Chronic Hepatitis B","enrollment":209},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT02201459","phase":"PHASE3","title":"Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-08","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT05970289","phase":"PHASE2","title":"Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2023-08-22","conditions":"Chronic Hepatitis B Virus Infection","enrollment":86},{"nctId":"NCT06650852","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)","status":"RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-10-31","conditions":"Chronic Hepatitis B Virus (HBV) Infection","enrollment":250},{"nctId":"NCT04035837","phase":"PHASE4","title":"The Clinical Cure Project of Chronic Hepatitis B in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-05-16","conditions":"Hepatitis B, Chronic","enrollment":30000},{"nctId":"NCT06923280","phase":"NA","title":"Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-05-01","conditions":"Hepatitis B, Chronic","enrollment":30},{"nctId":"NCT01986712","phase":"","title":"A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma","status":"COMPLETED","sponsor":"St. Luke's Hospital and Health Network, Pennsylvania","startDate":"2013-12","conditions":"Melanoma","enrollment":50},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT06491563","phase":"PHASE2","title":"Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-08-06","conditions":"For Treatment of Chronic Hepatitis B Virus Infection","enrollment":150},{"nctId":"NCT06734637","phase":"NA","title":"Efficacy and Safety of Peginterferon in ET and PV.","status":"RECRUITING","sponsor":"Zhenya Hong","startDate":"2024-11-20","conditions":"Essential Thrombocythemia, Polycythemia Vera","enrollment":40},{"nctId":"NCT00452023","phase":"PHASE2","title":"Pegasys® in Patients With Myeloproliferative Diseases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-04-07","conditions":"Myeloproliferative Disorders","enrollment":83},{"nctId":"NCT06091735","phase":"NA","title":"Clinical Study of Bowel Preparation Before Colonoscopy","status":"COMPLETED","sponsor":"Jinling Hospital, China","startDate":"2023-08-01","conditions":"Bowel Preparation","enrollment":444},{"nctId":"NCT03852433","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-31","conditions":"Chronic Hepatitis Delta","enrollment":175},{"nctId":"NCT04412863","phase":"PHASE2","title":"Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-07-03","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT06535048","phase":"","title":"Impact of Fatty Liver on Hepatitis B Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Second People's Hospital","startDate":"2015-01-01","conditions":"Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment","enrollment":500},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT04226950","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-01-10","conditions":"Essential Thrombocytopenia","enrollment":40},{"nctId":"NCT05395507","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-01","conditions":"Essential Thrombocytopenia","enrollment":194},{"nctId":"NCT04676724","phase":"PHASE2","title":"Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-28","conditions":"Hepatitis B","enrollment":108},{"nctId":"NCT04640129","phase":"PHASE4","title":"HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-01-01","conditions":"Liver Fibrosis","enrollment":336},{"nctId":"NCT04781647","phase":"PHASE2","title":"A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2021-02-18","conditions":"Chronic Hepatitis B","enrollment":54},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":"Non-Hodgkins Lymphoma","enrollment":27},{"nctId":"NCT05729139","phase":"PHASE1","title":"Cemiplimab/Peg-Interferon-α in Advanced CSCC","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2023-07","conditions":"Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT01935089","phase":"PHASE2","title":"Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2013-08-07","conditions":"HIV-1 Infection","enrollment":20},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT00134030","phase":"PHASE3","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-11-14","conditions":"Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1334},{"nctId":"NCT01369212","phase":"PHASE3","title":"Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-11","conditions":"Hepatitis B","enrollment":201},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":"Chronic Myeloid Leukemia in Remission","enrollment":214},{"nctId":"NCT02430194","phase":"PHASE2","title":"Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-12","conditions":"Chronic Hepatitis D Infection","enrollment":55},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT02430181","phase":"PHASE2","title":"Lonafarnib With and Without Ritonavir in HDV (LOWR-1)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-11","conditions":"Chronic Hepatitis D Infection","enrollment":21},{"nctId":"NCT01368497","phase":"PHASE3","title":"Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-09","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT01387763","phase":"PHASE3","title":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","status":"COMPLETED","sponsor":"Thomas Stauffer Larsen","startDate":"2012-01","conditions":"Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis","enrollment":202},{"nctId":"NCT03575208","phase":"PHASE2","title":"Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2019-02-13","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT04943679","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-06-15","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"HIV Infection, Hepatitis C Infection","enrollment":68},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT01587586","phase":"PHASE2","title":"Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2011-10-18","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT03588715","phase":"PHASE1","title":"Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)","status":"UNKNOWN","sponsor":"Luis Montaner","startDate":"2020-06-18","conditions":"HIV, HIV/AIDS, HIV-1 Infection","enrollment":15},{"nctId":"NCT02218047","phase":"PHASE3","title":"AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2014-11","conditions":"Polycythemia Vera","enrollment":170},{"nctId":"NCT00973219","phase":"NA","title":"Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2009-09","conditions":"Chronic Hepatitis B","enrollment":151},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT00525031","phase":"PHASE2","title":"Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08","conditions":"Melanoma","enrollment":55},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT03957629","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-11-06","conditions":"Hepatitis B, Liver Fibrosis","enrollment":186},{"nctId":"NCT00086541","phase":"PHASE3","title":"Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-06","conditions":"Chronic Hepatitis C","enrollment":515},{"nctId":"NCT01364090","phase":"PHASE4","title":"A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":93},{"nctId":"NCT01928511","phase":"PHASE4","title":"Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2014-01","conditions":"Chronic Hepatitis B","enrollment":254},{"nctId":"NCT02407080","phase":"PHASE1","title":"Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia","status":"COMPLETED","sponsor":"John Mascarenhas","startDate":"2015-04","conditions":"Polycythemia Vera, Essential Thrombocythemia","enrollment":13},{"nctId":"NCT03547154","phase":"PHASE2, PHASE3","title":"Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-10-22","conditions":"Chronic Myelogenous Leukemia","enrollment":344},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT01294618","phase":"PHASE2","title":"Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-03","conditions":"Chronic Myelogenous Leukemia","enrollment":60},{"nctId":"NCT02726789","phase":"PHASE2","title":"Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2012-10","conditions":"Hepatitis B, Chronic","enrollment":5},{"nctId":"NCT01295515","phase":"PHASE1, PHASE2","title":"Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-11","conditions":"HIV Infection","enrollment":7},{"nctId":"NCT01088659","phase":"PHASE3","title":"A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-16","conditions":"Hepatitis D, Chronic","enrollment":50},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT01265693","phase":"","title":"The Effect of Antiviral Therapy With Pegylated Interferon-alpha on Auditory Disability","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2011-01-09","conditions":"Hearing Loss, Sudden Deafness","enrollment":100},{"nctId":"NCT01758588","phase":"PHASE2","title":"Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-01","conditions":"Myelofibrosis","enrollment":8},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT02908763","phase":"PHASE4","title":"HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-08","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT02452814","phase":"","title":"Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-07","conditions":"HCV","enrollment":8},{"nctId":"NCT01193699","phase":"PHASE1, PHASE2","title":"Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2010-08","conditions":"Polycythemia Vera","enrollment":24},{"nctId":"NCT02508090","phase":"","title":"Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-02","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT01725204","phase":"PHASE2","title":"Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2012-09","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":40},{"nctId":"NCT01730508","phase":"","title":"An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11-20","conditions":"Hepatitis B, Chronic","enrollment":978},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00204529","phase":"PHASE3","title":"Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2004-10","conditions":"Melanoma","enrollment":901},{"nctId":"NCT03105310","phase":"PHASE2","title":"Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2016-01","conditions":"Hepatitis D, Chronic","enrollment":20},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00759109","phase":"PHASE3","title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-03","conditions":"Carcinoma, Hepatocellular","enrollment":150},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT00467077","phase":"PHASE2","title":"Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer","status":"TERMINATED","sponsor":"California Cancer Consortium","startDate":"2004-09","conditions":"Kidney Cancer","enrollment":21},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT00209209","phase":"PHASE3","title":"Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-01-14","conditions":"Lymphoma, Mantle-Cell","enrollment":570},{"nctId":"NCT01980290","phase":"","title":"Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2013-05","conditions":"Hepatitis, Chronic","enrollment":50},{"nctId":"NCT00861406","phase":"PHASE1","title":"Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-10","conditions":"Melanoma","enrollment":38},{"nctId":"NCT02829775","phase":"PHASE2, PHASE3","title":"A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma","enrollment":9},{"nctId":"NCT02118597","phase":"","title":"An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2014-05","conditions":"Hepatitis C, Chronic","enrollment":19},{"nctId":"NCT01949805","phase":"PHASE3","title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2013-09","conditions":"Polycythemia Vera","enrollment":257},{"nctId":"NCT00759200","phase":"PHASE2","title":"Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Chronic Hepatitis C","enrollment":525},{"nctId":"NCT01337375","phase":"PHASE1","title":"A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Hepatitis C, Chronic","enrollment":31},{"nctId":"NCT01798576","phase":"","title":"An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT01358864","phase":"PHASE3","title":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-06","conditions":"Hepatitis C, Chronic","enrollment":678},{"nctId":"NCT01399619","phase":"PHASE3","title":"Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":310},{"nctId":"NCT02120274","phase":"PHASE4","title":"Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C","status":"TERMINATED","sponsor":"Federal University of São Paulo","startDate":"2014-03","conditions":"RNA Virus Infections, Flaviviridae Infections, Hepatitis C","enrollment":85},{"nctId":"NCT01500616","phase":"PHASE3","title":"Telaprevir Open-Label Study in Co-Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":122},{"nctId":"NCT01531166","phase":"","title":"A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-09","conditions":"Chronic Hepatitis B","enrollment":500},{"nctId":"NCT01258101","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Hepatitis C, Chronic","enrollment":395},{"nctId":"NCT02822547","phase":"PHASE4","title":"Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2015-03","conditions":"Chronic Hepatitis B","enrollment":253},{"nctId":"NCT01330316","phase":"PHASE3","title":"A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-07","conditions":"Hepatitis C","enrollment":119}],"_emaApprovals":[],"_faersSignals":[{"count":56,"reaction":"ANAEMIA"},{"count":47,"reaction":"FATIGUE"},{"count":45,"reaction":"ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS"},{"count":32,"reaction":"NAUSEA"},{"count":30,"reaction":"RASH"},{"count":26,"reaction":"VOMITING"},{"count":23,"reaction":"DIARRHOEA"},{"count":22,"reaction":"DRUG INEFFECTIVE"},{"count":22,"reaction":"HEPATITIS C"},{"count":21,"reaction":"DYSPNOEA"}],"_approvalHistory":[],"publicationCount":658,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"pegylated interferon-alfa","genericName":"pegylated interferon-alfa","companyName":"Third Affiliated Hospital, Sun Yat-Sen University","companyId":"third-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon-alfa is a modified form of interferon-alfa that binds to interferon-alfa receptors on immune cells to enhance antiviral and anti-tumor immune responses. Used for Chronic hepatitis B, Chronic hepatitis C, Certain hematologic malignancies (e.g., chronic myeloid leukemia, melanoma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}